We work closely with client teams to define technology, market and product strategies and translate these into real-world operational plans. Such strategies can support fundraising and help to demonstrate differentiation of a client’s assets from those entering, or currently available, on the market. Our consultants use their industry experience together with in-depth primary research to determine favourable therapeutic areas which clients can target. We also consult with key opinion leaders to supplement this information, and even support mutual collaborations between our clients and other companies.
Our scope of work includes strategizing:
- corporate and business development
- target therapeutic profiles, portfolios and diversification
- preclinical and clinical product development
- competitive landscapes
- market entry and forecasting
- overall cost
Case study: Supporting radiopharmaceutical R&D
A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan.
Led by an expert in radiopharmaceuticals with 25 years’ experience in nuclear medicine R&D and business development, our radiopharmaceuticals consultants developed an R&D strategy.
We visited our client’s facilities and interviewed key members of staff to assess their current capability and infrastructure. We then interviewed several key opinion leaders to develop an up-to-date and clear understanding of the future opportunities in nuclear medicine.
We delivered three strategic options for the client to consider, ranging from semi-virtual through to fully integrated, and for each option set out the infrastructure, personnel and investment needed, expected timelines and likely return on investment.
We provided specific recommendations with respect to radioisotopes of special interest, unmet needs for new diagnostic tracers and set out a number of therapeutic strategies in major disease indications. To accelerate their entry into the field, we presented a number of promising in-licensing opportunities.
Further case studies regarding Therapeutic area strategy are available here.
Related Case Studies
Alacrita’s radiopharmaceuticals consultant has had a distinguished career in the nuclear medicine industry. For a recent radiopharmaceuticals strategy project for a major public/private investor in a BRIC territory, Alacrita...
Start-up support and funding
Alacrita worked with the CEO and Chairman of Evgen Ltd, a start-up biotech company, to successfully secure a Series A financing. Alacrita developed a rational development strategy for Evgen’s...
Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the quality of a...
Supporting radiopharmaceutical R&D
A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Solution Led by an expert in radiopharmaceuticals with...
Strategy for biomarker identification technology
Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of candidate...
Immunotherapy strategy for a radiotherapy company
A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that radiation...
It has always been a pleasure to work with you… I really enjoyed and highly appreciate your professionalism, availability and willingness to help out in many short-term due diligence activities. Thank you for that!